The Efficacy and Safety of Selinexor in Combination with Ruxolitinib in Ruxolitinib-Treated Myelofibrosis Patients: the Interim Analysis of a Prospective, Open-Label, Multicenter, Parallel-Cohort, Phase 2 Study

被引：3

作者：

Duan, Minghui ^{[1
]}

Ma, Lan ^{[2
]}

Wu, Qiuling ^{[3
]}

Liang, Hong ^{[4
]}

Wang, Wei ^{[5
]}

Wu, Shaoling ^{[5
]}

Mu, Lijun ^{[6
]}

Lin, Hai ^{[7
]}

Zhou, Hebing ^{[8
]}

Shi, Hong-Xia ^{[9
]}

Wang, Jinghua ^{[10
]}

Jing, Hongmei ^{[2
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Hematol, Beijing, Peoples R China

[2] Peking Univ Third Hosp, Beijing, Peoples R China

[3] Huazhong Univ Sci & Technol, Inst Hematol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China

[4] Harbin Inst Hematol & Oncol, Dept Hematol & Oncol, Haerbin, Peoples R China

[5] Qingdao Univ, Affiliated Hosp, Dept Hematol, Qingdao, Peoples R China

[6] Dalian Med Univ, Hosp 2, Dalian, Peoples R China

[7] First Hosp Jilin Univ, Dept Hematol, Jilin, Jilin, Peoples R China

[8] Capital Med Univ, Beijing Luhe Hosp, Dept Hematol, Beijing, Peoples R China

[9] Peking Univ, Natl Clin Res Ctr Hematol Dis, Beijing Key Lab Hematopoiet Stem Cell Transplanta, Inst Hematol,Peoples Hosp, Beijing, Peoples R China

[10] Harbin Med Univ, Affiliated Hosp 2, Harbin, Heilongjiang, Peoples R China

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-188037

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[1] Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis
Norio Komatsu
Keita Kirito
Kazuya Shimoda
Takayuki Ishikawa
Kohshi Ohishi
Kazuma Ohyashiki
Naoto Takahashi
Hikaru Okada
Taro Amagasaki
Toshio Yonezu
Koichi Akashi
International Journal of Hematology, 2017, 105 : 309 - 317
[2] Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis
Komatsu, Norio
Kirito, Keita
Shimoda, Kazuya
Ishikawa, Takayuki
Ohishi, Kohshi
Ohyashiki, Kazuma
Takahashi, Naoto
Okada, Hikaru
Amagasaki, Taro
Yonezu, Toshio
Akashi, Koichi
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 105 (03) : 309 - 317
[3] Erratum to: Assessing the safety and efficacy of ruxolitinib in a multicenter, open-label study in Japanese patients with myelofibrosis
Norio Komatsu
Keita Kirito
Kazuya Shimoda
Takayuki Ishikawa
Kohshi Ohishi
Kazuma Ohyashiki
Naoto Takahashi
Hikaru Okada
Taro Amagasaki
Toshio Yonezu
Koichi Akashi
International Journal of Hematology, 2017, 105 : 387 - 387
[4] Assessing the Safety and Efficacy of Ruxolitinib in a Multicenter, Open-Label, Expanded-Access Study in Japanese Patients with Myelofibrosis (MF)
Kirito, Keita
Komatsu, Norio
Shimoda, Kazuya
Okada, Hikaru
Amagasaki, Taro
Yonezu, Toshio
Akashi, Koichi
BLOOD, 2015, 126 (23)
[5] Navitoclax plus ruxolitinib in JAK inhibitor-naive patients with myelofibrosis: Preliminary safety and efficacy in a multicenter, open-label phase 2 study.
Passamonti, Francesco
Foran, James M.
Tandra, Anand
De Stefano, Valerio
Fox, Maria Laura
Mattour, Ahmad Hatem
McMullin, Mary Frances
Perkins, Andrew
Rodriguez-Macias, Gabriela
Sibai, Hassan
Qin, Qin Q.
Potluri, Jalaja
How, Jonathan B.
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[6] A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis
Oritani, Kenji
Okamoto, Shinichiro
Tauchi, Tetsuzo
Saito, Shigeki
Ohishi, Kohshi
Handa, Hiroshi
Takenaka, Katsuto
Gopalakrishna, Prashanth
Amagasaki, Taro
Ito, Kazuo
Akashi, Koichi
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (03) : 295 - 304
[7] A multinational, open-label, phase 2 study of ruxolitinib in Asian patients with myelofibrosis: Japanese subset analysis
Kenji Oritani
Shinichiro Okamoto
Tetsuzo Tauchi
Shigeki Saito
Kohshi Ohishi
Hiroshi Handa
Katsuto Takenaka
Prashanth Gopalakrishna
Taro Amagasaki
Kazuo Ito
Koichi Akashi
International Journal of Hematology, 2015, 101 : 295 - 304
[8] Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
Talpaz, Moshe
Erickson-Viitanen, Susan
Hou, Kevin
Hamburg, Solomon
Baer, Maria R.
JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
[9] Evaluation of an alternative ruxolitinib dosing regimen in patients with myelofibrosis: an open-label phase 2 study
Moshe Talpaz
Susan Erickson-Viitanen
Kevin Hou
Solomon Hamburg
Maria R. Baer
Journal of Hematology & Oncology, 11
[10] Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are intolerant to ruxolitinib: A single-arm, open-label, phase 2, multicenter study
Zhang, Yi
Zhou, Hu
Duan, Minghui
Gao, Sujun
He, Guangsheng
Jing, Hongmei
Li, Junmin
Ma, Liangming
Zhu, Huanling
Chang, Chunkang
Du, Xin
Hong, Mei
Li, Xin
Liu, Qingchi
Wang, Wei
Xu, Na
Yang, Haiping
Lu, Binhua
Yin, Hewen
Wu, Liqing
Suo, Shanshan
Zhao, Qingwei
Xiao, Zhijian
Jin, Jie
AMERICAN JOURNAL OF HEMATOLOGY, 2023, : 1588 - 1597

← 1 2 3 4 5 →